Lataa...
Anti-platelet therapy: glycoprotein IIb-IIIa antagonists
Glycoprotein (GP) IIb-IIIa antagonists inhibit the aggregation of activated platelets. Three agents are approved for clinical use. In this review, the characteristics of each agent, their pharmacodynamic profile, results in pivotal clinical trials and the associated clinical implications are discuss...
Tallennettuna:
| Päätekijä: | |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Blackwell Science Inc
2011
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3195742/ https://ncbi.nlm.nih.gov/pubmed/21906121 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2125.2010.03879.x |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|